NASDAQ:OYST - Oyster Point Pharma Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $20.00
  • Forecasted Upside: 178.16 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$7.19
▲ +0.18 (2.57%)

This chart shows the closing price for OYST by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Oyster Point Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OYST and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OYST

Analyst Price Target is $20.00
▲ +178.16% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Oyster Point Pharma in the last 3 months. The average price target is $20.00, with a high forecast of $23.00 and a low forecast of $15.00. The average price target represents a 178.16% upside from the last price of $7.19.

This chart shows the closing price for OYST for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in Oyster Point Pharma. This rating changed within the last month from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/21/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/22/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/20/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/18/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/16/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/17/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/16/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/15/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/11/2022Chardan CapitalInitiated CoverageBuy$22.00Low
7/18/2022HC WainwrightInitiated CoverageBuy$20.00Low
5/27/2022Piper SandlerLower Price Target$60.00 ➝ $15.00Low
11/9/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$30.00 ➝ $23.00High
10/27/2020Lifesci CapitalReiterated RatingOutperformMedium
3/6/2020JPMorgan Chase & Co.Boost Price Target$25.00 ➝ $50.00Low
2/28/2020Piper SandlerBoost Price Target$35.00 ➝ $60.00High
11/25/2019JPMorgan Chase & Co.Initiated CoverageOverweight$26.00High
11/25/2019CowenInitiated CoverageOutperform$40.00 ➝ $40.00High
11/25/2019Piper Jaffray CompaniesInitiated CoverageOverweight$35.00High
(Data available from 8/16/2017 forward)

News Sentiment Rating

0.57 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/18/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/17/2022
  • 5 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/19/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/18/2022
  • 6 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/18/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/17/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/17/2022
  • 4 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/16/2022

Current Sentiment

  • 4 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Oyster Point Pharma logo
Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.
Read More

Today's Range

Now: $7.19
Low: $6.65
High: $7.42

50 Day Range

MA: $5.25
Low: $3.60
High: $8.38

52 Week Range

Now: $7.19
Low: $3.46
High: $19.98

Volume

115,474 shs

Average Volume

139,192 shs

Market Capitalization

$192.91 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.08

Frequently Asked Questions

What sell-side analysts currently cover shares of Oyster Point Pharma?

The following Wall Street sell-side analysts have issued stock ratings on Oyster Point Pharma in the last twelve months: Chardan Capital, HC Wainwright, JPMorgan Chase & Co., and Piper Sandler.
View the latest analyst ratings for OYST.

What is the current price target for Oyster Point Pharma?

4 Wall Street analysts have set twelve-month price targets for Oyster Point Pharma in the last year. Their average twelve-month price target is $20.00, suggesting a possible upside of 178.2%. JPMorgan Chase & Co. has the highest price target set, predicting OYST will reach $23.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $15.00 for Oyster Point Pharma in the next year.
View the latest price targets for OYST.

What is the current consensus analyst rating for Oyster Point Pharma?

Oyster Point Pharma currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OYST will outperform the market and that investors should add to their positions of Oyster Point Pharma.
View the latest ratings for OYST.

What other companies compete with Oyster Point Pharma?

How do I contact Oyster Point Pharma's investor relations team?

Oyster Point Pharma's physical mailing address is 202 CARNEGIE CENTER SUITE 109, PRINCETON NJ, 08540. The company's listed phone number is 609-382-9032 and its investor relations email address is [email protected] The official website for Oyster Point Pharma is www.oysterpointrx.com. Learn More about contacing Oyster Point Pharma investor relations.